Pepstatin A

With high selectivity, low cross-reactivity, stability, and ease of use, the product has evolved from an early protease tool drug to applications across biochemistry and molecular biology, protein purification, disease mechanism research, drug screening, virology, neuroscience, food science, and other fields, establishing itself as an irreplaceable classic small-molecule tool in life science and medical research.

The most central and classic application of it is the identification, classification, and activity assay of aspartic proteases. The aspartic protease family is widely involved in physiological and pathological processes including protein degradation, antigen presentation, apoptosis, and tissue remodeling. However, their activity is easily affected by pH, metal ions, and protease inhibitors, making it difficult for traditional detection methods to distinguish enzyme types.

It is highly specific for aspartic proteases and barely inhibits serine, cysteine, or metalloproteases, making it the gold-standard reagent for enzyme classification and identification.

In enzymatic characterization, researchers use it to determine the optimal pH, inhibition constant Ki, binding kinetics, and substrate specificity of target proteases. Gradient concentrations of Pepstatin A allow precise calculation of enzyme–inhibitor affinity and classification of proteases into canonical or novel aspartic protease subtypes.

It is also used for in situ localization of proteases in tissues and cells. Combined with immunofluorescence and enzyme histochemical staining, it directly visualizes the distribution of cathepsin D/E in lysosomes, cytoplasm, and cell membranes, providing direct evidence for understanding protease roles in cellular homeostasis.

Furthermore, it is widely used in physiological protease knockdown models. Without altering gene expression, it specifically inhibits enzyme activity to observe changes in cell phenotype, signaling pathways, and protein degradation profiles, distinguishing the effects of "enzyme expression level" versus "enzyme activity" and providing a reversible, controllable, dose-dependent method for functional validation.

By efficiently inhibiting aspartic proteases, the product has become a core component of protease inhibitor cocktail formulations.

It is commonly combined with EDTA, leupeptin, PMSF, aprotinin, etc., to block metalloproteases, cysteine proteases, and serine proteases respectively, achieving broad-spectrum protection. Stable in both acidic and neutral environments, the product effectively protects membrane proteins, nuclear proteins, cytoplasmic proteins, and secreted proteins, especially suitable for the extraction of labile, low-abundance, and active enzymes.

In cancer research, high cathepsin D expression correlates with tumor invasion, metastasis, and poor prognosis. The product inhibits cancer cell invasion and migration, reduces matrix degradation, and decreases angiogenesis in vitro and in animal models, validating cathepsin D as a key driver of tumor progression. It also modulates autophagy–apoptosis balance in tumor cells, supporting studies of protease-dependent cell death pathways.

In renal disease and hypertension, renin - the rate-limiting enzyme of the renin–angiotensin system - is an aspartic protease. Pepstatin A specifically inhibits renin activity and blocks angiotensin production, enabling hypertensive inhibition models for screening and evaluating novel antihypertensive drug targets.

β-secretase (BACE1) is a key aspartic protease that cleaves the amyloid precursor protein (APP) to generate Aβ amyloid, whose aggregation is ahallmark of Alzheimer's disease (AD). The product significantly inhibits β-secretase, making it a vital tool in AD mechanism research.

By blocking Aβ production, researchers use it to observe neuronal survival, synaptic function, amyloid plaque deposition, and tau hyperphosphorylation, validating β-secretase as a therapeutic target. It also reduces abnormal protein degradation and oxidative stress in neurons, supporting studies of lysosomal dysfunction in neurodegeneration.

Many viruses rely on host or virally encoded aspartic proteases for replication, maturation, and release. The most prominent example is HIV protease, which is essential for processing viral polyproteins and virion maturation and belongs to the aspartic protease family. It inhibits HIV protease and blocks virion maturation, and was widely used in early anti-HIV drug screening models.

Beyond HIV, it helps study how other viruses (including some coronaviruses, herpesviruses, and hepatitis-related viruses) exploit host proteases during their life cycles. Specific inhibition of aspartic proteases helps determine viral dependence on these enzymes, supporting broad-spectrum antiviral strategies.

In the food industry, endogenous aspartic proteases cause excessive tenderization, flavor deterioration, soft texture, and shortened shelf life in meat, fish, and dairy products during storage and processing. As a naturally derived protease inhibitor, the product is used for food quality control.

In meat processing, it regulates proteolysis to improve tenderness and water-holding capacity while avoiding bitter peptides from over-degradation. In dairy and fermented foods, it controls proteolysis during fermentation to stabilize texture and flavor. It is also used to detect aspartic protease activity in foods, assessing raw material freshness, processing intensity, and product stability, supporting the development of food quality standards.

In basic research, it remains a core tool for dissecting aspartic protease mechanisms and will play a greater role in identifying novel proteases as proteomics advances. In medicine, its potential in epilepsy, malaria, and other diseases is emerging, supporting disease imaging and target validation. In the food industry, it will be further used for quality control and freshness detection, aligning with green food development.

Nanotechnology and targeted delivery systems can overcome poor blood–brain barrier penetration and short in vivo half-life. The productconjugated nanocarriers enable precise targeting to lesions and improved bioavailability, driving its transition from a research reagent to a clinical candidate molecule and providing new therapeutic approaches for neurodegenerative diseases, cancer, and other disorders.